We showed here an increase in total SOD activity, catalase, GPx1 and GPx4 gene expressions, as well as an increase in the mitochondrial redox state of fibroblasts from sPD patients after treatment with AntiOxCIN4, suggesting NRF2 regulation (Fig. 13). The gene discussed is GPX4; the disease is Platelet storage pool disease.